Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles

Vaccine

Volumn 32, Issue 17, 2014, Pages 1921-1931

  Li, Tingdong ^a   Lin, Haijun ^a   Zhang, Yue ^a   Li, Min ^a   Wang, Daning ^a   Che, Yaojian ^a   Zhu, Yinbin ^a   Li, Shaowei ^a   Zhang, Jun ^a   Ge, Shengxiang ^a   Zhao, Qinjian ^a   Xia, Ningshao ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

Diarrhea score; Double layered particle; Maternal antibody; Post purification assembly; Rotavirus; Virus like particles

Indexed keywords

MATERNAL ANTIBODY; PROTEIN VP2; PROTEIN VP6; RECOMBINANT VACCINE; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG PURIFICATION; DRUG SAFETY; ESCHERICHIA COLI; FEMALE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROTAVIRUS; THERMOSTABILITY; VACCINE PRODUCTION; VIRION; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS PARTICLE;

DIARRHEA SCORE; DOUBLE-LAYERED PARTICLE; MATERNAL ANTIBODY; POST PURIFICATION ASSEMBLY; ROTAVIRUS; VIRUS-LIKE PARTICLES;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; ESCHERICHIA COLI; FEMALE; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84896313766     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.093     Document Type: Article

References (56)

1. Tate J.E., Burton A.H., Boschi-Pinto C., Steele A.D., Duque J., Parashar U.D. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infectious Diseases 2012, 12(2):136-141.
2. Parashar U.D., Hummelman E.G., Bresee J.S., Miller M.A., Glass R.I. Global illness and deaths caused by rotavirus disease in children. Emerging Infectious Diseases 2003, 9(5):565-572.
3. Parashar U.D., Glass R.I. Rotavirus vaccines-early success, remaining questions. New England Journal of Medicine 2009, 360(11):1063-1065.
4. Murphy T.V., Gargiullo P.M., Massoudi M.S., Nelson D.B., Jumaan A.O., Okoro C.A., et al. Intussusception among infants given an oral rotavirus vaccine. New England Journal of Medicine 2001, 344(8):564-572.
5. Linhares A.C., Velázquez F.R., Pérez-Schael I., Sáez-Llorens X., Abate H., Espinoza F., et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008, 371(9619):1181-1189.
6. Plosker G.L. Pentavalent rotavirus vaccine (RotaTeq(R)): a review of its use in the prevention of rotavirus gastroenteritis in Europe. Drugs 2010, 70(9):1165-1188.
7. Snelling T.L., Andrews R.M., Kirkwood C.D., Culvenor S., Carapetis J.R. Case-control evaluation of the effectiveness of the G1P [8] human rotavirus vaccine during an outbreak of rotavirus G2P [4] infection in Central Australia. Clinical Infectious Diseases 2011, 52(2):191-200.
8. Wang F.T., Mast T.C., Glass R.J., Loughlin J., Seeger J.D. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010, 125(2):e208-e213.
9. Sow S.O., Tapia M., Haidara F.C., Ciarlet M., Diallo F., Kodio M., et al. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine 2012, 30(Suppl 1):A71-A78.
10. Cunliffe N.A., Witte D., Ngwira B.M., Todd S., Bostock N.J., Turner A.M., et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine 2012, 30(Suppl 1):A36-A43.
11. Zaman K., Anh D.D., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:568-570.
12. Patel M., Pedreira C., De Oliveira L., et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009, 301(21):2243-2251.
13. Yen C., Jakob K., Esona M.D., Peckham X., Rausch J., Hull J.J., et al. Detection of fecal shedding of rotavirus vaccine in infants following their first dose of pentavalent rotavirus vaccine. Vaccine 2011, 29(24):4151-4155.
14. Anderson E.J. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infectious Diseases 2008, 8(10):642-649.
15. Patel N.C., Hertel P.M., Estes M.K., de la Morena M., Petru A.M., Noroski L.M., et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. New England Journal of Medicine 2010, 362(4):314-319.
16. Payne D.C., Edwards K.M., Bowen M.D., Keckley E., Peters J., Esona M.D., et al. Sibling transmission of vaccine-derived rotavirus (RotaTeq) associated with rotavirus gastroenteritis. Pediatrics 2010, 125(2):e438-e441.
17. Zhao Q., Li S., Yu H., Xia N., Modis Y. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends in Biotechnology 2013, 31(11):654-663.
18. Kushnir N., Streatfield S.J., Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 2012, 31(1):58-83.
19. McAleer W.J., Buynak E.B., Maigetter R.Z., Wampler D.E., Miller W.J., Hilleman M.R. Human hepatitis B vaccine from recombinant yeast. Nature 1984, 307:178-180.
20. Bertolotti-Ciarlet A., Ciarlet M., Crawford S.E., Conner M.E., Estes M.K. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine 2003, 21(25-26):3885-3900.
21. Gonzalez S.A., Affranchino J.L. Assembly of double-layered virus-like particles in mammalian cells by coexpression of human rotavirus VP2 and VP6. Journal of General Virology 1995, 76(9):2357-2360.
22. McNeal M.M., Rae M.N., Conner M.E., Ward R.L. Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21. Virology 1998, 243(1):158-166.
23. Palomares L.A., Ramírez O.T. Challenges for the production of virus-like particles in insect cells: the case of rotavirus-like particles. Biochemical Engineering Journal 2009, 45(3):158-167.
24. Yang C., Pan H., Wei M., Zhang X., Wang N., Gu Y., et al. Hepatitis E virus capsid protein assembles in 4M urea in the presence of salts. Protein Science 2013, 22(3):314-326.
25. Pourasgari F., Salmanian A.H. The comparison of folding of the recombinant rotavirus VP2 expressed in E. coli and eukaryotic cells by electron microscopy. FEBS Journal 2005, 516.
26. Zhao Q., Chen W., Chen Y., Zhang L., Zhang J., Zhang Z. Self-assembled virus-like particles from rotavirus structural protein VP6 for targeted drug delivery. Bioconjugate Chemistry 2011, 22(3):346-352.
27. Mellado M.C.M., Mena J.A., Lopes A., Ramírez O.T., Carrondo M.J., Palomares L.A., et al. Impact of physicochemical parameters on in vitro assembly and disassembly kinetics of recombinant triple-layered rotavirus-like particles. Biotechnology and Bioengineering 2009, 104(4):674-686.
28. Ward R. Mechanisms of protection against rotavirus infection and disease. Pediatric Infectious Disease Journal 2009, 28(3):S57.
29. Coste A., Sirard J.C., Johansen K., Cohen J., Kraehenbuhl J.P. Nasal immunization of mice with virus-like particles protects offspring against rotavirus diarrhea. Journal of Virology 2000, 74(19):8966-8971.
30. Sambrook J., Russell D. Molecular cloning a laboratory manual 2001, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 3rd ed.
31. Chang K.H., Park C.H., Park J.H., Chung I.S. Optimal cell density and multiplicity of infection for the propagation of human rotavirus in monkey kidney cells. Biotechnology Techniques 1999, 13(11):757-759.
32. Feng N., Lawton J.A., Gilbert J., Kuklin N., Vo P., Prasad B.V.V., et al. Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb. Journal of Clinical Investigation 2002, 109(9):1203-1213.
33. Zhang C. Hybridoma technology for the generation of monoclonal antibodies. Antibody methods and protocols 2012, 117-135. Humana Press, New York, NY.
34. Nakane P.K., Kawaoi A. Peroxidase-labeled antibody a new method of conjugation. Journal of Histochemistry and Cytochemistry 1974, 22(12):1084.
35. Li S., Tang X., Seetharaman J., Yang C., Gu Y., Zhang J., et al. Dimerization of hepatitis E virus capsid protein E2s domain is essential for virus-host interaction. PLoS Pathogens 2009, 5(8):e1000537.
36. Zhao Q., Wang Y., Abraham D., Towne V., Kennedy R., Sitrin R.D. Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat-and redox-treatment. Biochemical and Biophysical Research Communications 2011, 408(3):447-453.
37. ® maturation and potential epitope improvements with redox treatment: multifaceted biochemical and immunochemical characterization. Vaccine 2011, 29(45):7936-7941.
38. Zhao Q., Modis Y., High K., Towne V., Meng Y., Wang Y., et al. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. Virology Journal 2012, 9(1):52.
39. Lepault J., Petitpas I., Erk I., Navaza J., Bigot D., Dona M., et al. Structural polymorphism of the major capsid protein of rotavirus. EMBO Journal 2001, 20:1498-1507.
40. Pesavento J.B., Crawford S.E., Estes M.K., Prasad B.V. Rotavirus proteins: structure and assembly. Current Topics in Microbiology Immunology 2006, 309:189-219.
41. Zhao Q., Allen M.J., Wang Y., Wang B., Wang N., Shi L., et al. Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles. Nanomedicine 2012, 8(7):1182-1189.
42. Redmond M., Ijaz M., Parker M., Sabara M., Dent D., Gibbons E., et al. Assembly of recombinant rotavirus proteins into virus-like particles and assessment of vaccine potential. Vaccine 1993, 11(2):273-281.
43. Charpilienne A., Lepault J., Rey F., Cohen J. Identification of rotavirus VP6 residues located at the interface with VP2 that are essential for capsid assembly and transcriptase activity. Journal of Virology 2002, 76(15):7822-7831.
44. Libersou S., Siebert X., Ouldali M., Estrozi L.F., Navaza J., Charpilienne A., et al. Geometric mismatches within the concentric layers of rotavirus particles: a potential regulatory switch of viral particle transcription activity. Journal of Virology 2008, 82(6):2844-2852.
45. Zeng C.Q-Y., Labbé M., Cohen J., Prasad B., Chen D., Ramig R.F., et al. Characterization of rotavirus VP2 particles. Virology 1994, 201(1):55-65.
46. Settembre E.C., Chen J.Z., Dormitzer P.R., Grigorieff N., Harrison S.C. Atomic model of an infectious rotavirus particle. EMBO Journal 2011, 30(2):408-416.
47. Choi A.H.C., Basu M., McNeal M.M., Flint J., VanCott J.L., Clements J.D., et al. Functional mapping of protective domains and epitopes in the rotavirus VP6 protein. Journal of Virology 2000, 74(24):11574-11580.
48. Corthesy B., Benureau Y., Perrier C., Fourgeux C., Parez N., Greenberg H., et al. Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. Journal of Virology 2006, 80(21):10692-10699.
49. Schwartz-Cornil I., Benureau Y., Greenberg H., Hendrickson B.A., Cohen J. Heterologous protection induced by the inner capsid proteins of rotavirus requires transcytosis of mucosal immunoglobulins. Journal of Virology 2002, 76(16):8110-8117.
50. Tamminen K., Lappalainen S., Huhti L., Vesikari T., Blazevic V. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PloS One 2013, 8(7):e70409.
51. Blazevic V., Lappalainen S., Nurminen K., Huhti L., Vesikari T. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine 2011, 29(45):8126-8133.
52. Lappalainen S., Tamminen K., Vesikari T., Blazevic V. Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles. Human Vaccines and Immunotherapeutics 2013, 9(9.).
53. Jiang B., Gentsch J.R., Glass R.I. The role of serum antibodies in the protection against rotavirus disease: an overview. Clinical Infectious Diseases 2002, 34(10):1351-1361.
54. Offit P., Clark H. Protection against rotavirus-induced gastroenteritis in a murine model by passively acquired gastrointestinal but not circulating antibodies. Journal of Virology 1985, 54(1):58-64.
55. Choi A.H.C., McNeal M.M., Basu M., Bean J.A., VanCott J.L., Clements J.D., et al. Functional mapping of protective epitopes within the rotavirus VP6 protein in mice belonging to different haplotypes. Vaccine 2003, 21(7-8):761-767.
56. Ciarlet M., Crawford S.E., Barone C., Bertolotti-Ciarlet A., Ramig R.F., Estes M.K., et al. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. Journal of Virology 1998, 72(11):9233-9246.